Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Incyte Corporation
Woman and Man Max 99 years
Incyte Corporation
Update Il y a 4 ans
A randomized, double-blind, study of ruxolitinib or placebo in combination with capecitabine as second line treatent for Subjects With Pancreatic cancer (The JANUS 1 Study)
To evaluate and compare the OS of subjects with advanced or metastatic adenocarcinoma of the pancreas when treated with ruxolitinib in combination with capecitabine versus capecitabine alone.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Incyte Corporation
Update Il y a 4 ans
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies
To evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine the pharmacologically active dose (PAD) and maximum tolerated dose (MTD) of INCB054828, alone as a monotherap...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Incyte Corporation
Update Il y a 4 ans
A Phase 2 Study of Ruxolitinib With Capecitabine in Subjects With Advanced HER2-Negative Breast Cancer
To evaluate and compare the OS of subjects with advanced or metastatic HER2 negative breast cancer when treated with ruxolitinib in combination with capecitabine versus capecitabine alone.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Incyte Corporation
Update Il y a 4 ans
A Phase 2, Open-Label, Single-Agent, Multicenter Study to investigate the Efficacy and Safety of INCB054828 in Subjects Advanced Bladder cancer with FGF/FGFR Alterations
To evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring fibroblast growth factor (FGF)/fibro...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2